Abstract Body

Background

South African antiretroviral therapy (ART) guidelines recommend dolutegravir (DTG) based regimens. Although DTG resistance is infrequently reported, it is paramount to identify individuals at risk for resistance. We assessed the use of plasma DTG (pDTG) drug-exposure (DE) testing as a triaging tool to identify individuals at highest risk for DTG resistance. Additionally, we assessed the use of Oxford Nanopore Technologies (ONT) sequencing in a public health setting for HIVDR testing. 

Methods

Sanger sequences were available for 97 individuals who had resistance tests requested when failing DTG-based treatment in South Africa. Remnant specimens were used to qualitatively assess pDTG DE using an LC-MS/MS method. Nanopore sequences were obtained for 55 specimens using the ONT native barcoding kit for amplicons (SQK-NBD114.96). Nanopore and Sanger sequences were analysed with NanoRecall and Recall respectively at a 25% threshold and submitted to Stanford HIVdb V9.6.

Results

Most individuals were female (70.1%) with a median age of 35 (IQR: 20-44) and log10 viral load of 4.8 (IQR: 3.2-5.7). The median time of DTG treatment was 13.8 months (IQR: 6.1-26.3). DTG resistance was detected in 19.5% (19/97) individuals by Sanger sequencing (Table). Individuals with detectable pDTG (45.4%), were more likely to have DTG resistance (OR: 9.01; 95% CI 2.41 – 35.59, p=0.001). Undetectable pDTG predicted the absence of DTG resistance with high accuracy (NPV: 94.2%, 95% CI: 85.1-97.9). Multivariate logistic regression demonstrated there was no association between pDTG DE results and VL, sex, duration on DTG, and prior PI exposure. However, individuals with prior ART (OR: 15.9; 95% CI: 1.8-141.7, p=0.013) and specially NNRTI exposure (OR: 0.14; 95% CI: 0.03-0.59, p=0.008) were more likely to have detectable pDTG, as were older individuals (OR: 1.04; 95% CI: 1.0-1.1, p=0.019). Resistance mutations detected by Sanger and ONT had a 96.4% (95% CI: 98.3-100) and 97.1% (95% CI: 98.3-100) pairwise identity for integrase and protease-reverse transcriptase respectively.

Conclusions

We demonstrated that pDTG DE testing can accurately predict the absence of DTG resistance and can therefore be considered an adequate screening method to identify individuals who do not require HIVDR testing, decreasing the financial burden associated with HIVDR testing. Additionally, nanopore sequencing may be a suitable alternative to conventional HIVDR testing with excellent concordance between mutation detection by both technologies.

Table or Figure